The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks' gestation. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Collins, Carmel; Gibson, Robert; Makrides, Maria; McPhee, Andrew; Sullivan, Thomas; Davis, Peter; Thio, Marta; Simmer, Karen; Rajadurai, Victor
• Is Part Of: BMC pediatrics. Volume 16:Issue 1(2016)
• Page Start: 1
• Page End: 9
• Publication Date: 2016-12
• Subjects: Infant -- Preterm -- Bronchopulmonary dysplasia -- Docosahexaenoic acid -- n-3 long chain polyunsaturated fatty acids; Pediatrics -- Periodicals; 618.920005
• DOI: 10.1186/s12887-016-0611-0
• Languages: English
• ISSNs: 1471-2431

Abstract

Abstract Background Bronchopulmonary dysplasia (BPD) is a major cause of mortality and long-term respiratory and neurological morbidity in very preterm infants. While survival rates of very preterm infants have increased over the past two decades there has been no decrease in the rate of BPD in surviving infants. Evidence from animal and human studies has suggested potential benefits of docosahexaenoic acid (DHA), an n-3 long chain polyunsaturated fatty acid, in the prevention of chronic lung disease. This randomised controlled trial aims to determine the effectiveness of supplementary DHA in reducing the rate of BPD in infants less than 29 weeks&#39; gestation. Methods/design This is a multicentre, parallel group, randomised, blinded and controlled trial. Infants born less than 29 weeks&#39; gestation, within 3 days of first enteral feed and with parent informed consent are eligible to participate. Infants will be randomised to receive an enteral emulsion containing DHA or a control emulsion without DHA. The DHA emulsion will provide 60 mg/kg/day of DHA. The study emulsions will continue to 36 weeks&#39; postmenstrual age (PMA). The primary outcome is BPD as assessed by the requirement for supplemental oxygen and/or assisted ventilation at 36 weeks&#39; PMA. Secondary outcomes include the composite of death or BPD; duration of respiratory support and hospitalisation, major neonatal morbidities. The target sample size is 1244 infants (622 per group), which will provide 90 % power to detect a clinically meaningful absolute reduction of 10 % in the incidence of BPD between the DHA and control emulsion (two tailed α =0.05). Discussion DHA supplementation has the potential to reduce respiratory morbidity in very preterm infants. This multicentre trial will provide evidence on whether an enteral DHA supplement reduces BPD in very preterm infants. Trial registration Australia and New Zealand Clinical Trial Registry:ACTRN12612000503820 . Registered 09 May 2012.